RhuDex: Phase I started

MediGene began an open-label, U.K. Phase I trial to evaluate 2 oral formulations of RhuDex in up to 12 healthy male volunteers. RhuDex uses CD80 antagonists licensed from Active Biotech under a 2002 d...